Cure My Disease

Don't miss your cure!

 Log in / Sign up

New microRNA test could spare thousands from unnecessary thyroid surgery

NCT ID NCT04285476

Diagnosis Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new way to analyze thyroid nodules that look suspicious but not clearly cancerous. Researchers are checking if a set of microRNA molecules can better predict which nodules are actually cancer. The goal is to help patients avoid unnecessary surgery. The study involves 71 adults with thyroid nodules that need further testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

71 people

The number who actually took part.

Started

Jun 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Man or woman whose Age is ≥ 18 years 2. Patient requiring ultrasound for thyroid nodule scanning with established indication of FNAC 3. Patient with Bethesda 3, 4 and 5 thyroid nodule 4. Informed patient and signed informed consent received 5. Patient affiliated to a French medical coverage system Exclusion Criteria: 1. Patient under guardianship, curatorship or safeguarding of justice 2. Patient whose medical or psychological conditions do not permit them to complete the study or to sign the consent, 3. Patient with metastatic cancer distinct from thyroid cancer 4. Patient who has stopped treatment (chemotherapy / immunotherapy) for cancer for less than 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid cancer

Contacts and locations

Locations

  • CHU de Nîmes

    Nîmes, 30029, France

  • CHU de Toulouse

    Toulouse, Haute-Garonne, 31000, France

  • Institut régional du Cancer de Montpellier

    Montpellier, Hérault, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.